Δευτέρα 10 Απριλίου 2017

UK cost agency turns down Bristol drug for head and neck cancer - Nasdaq


Nasdaq

UK cost agency turns down Bristol drug for head and neck cancer
Nasdaq
LONDON, April 11 (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE said on Tuesday that Bristol-Myers Squibb's <BMY.N> immunotherapy drug Opdivo was not worth using on the state health service for treating head and neck cancer due to ...

and more »


from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oZKwAM
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις